FLT3 and acute myeloid leukemia: In line with this view, BM-MSC-exosomes from AML patients, but not from healthy donors, were shown to protect AML cells from chemotherapy (fms-like tyrosine kinase 3 (FLT3) inhibitor AC220) [60].